The First People's Hospital of Changzhou Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Changzhou China (1918)

Organization Overview

First Clinical Trial
2008
NCT02423226
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

jiangjingting | the First People' Hospital of Changzhou | The First People's Hospital of Changzhou

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Aneurysm (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Cholangiocarcinoma (Phase 3)

Colorectal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 2)

Glioma (Phase 4)

Hemorrhage (Phase 3)

Intracranial Aneurysm (Phase 3)

Lymphoma (Phase 4)

Lymphoma, B-Cell (Phase 4)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasm Metastasis (Phase 3)

Ovarian Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Subarachnoid Hemorrhage (Phase 3)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial APIs: 42